A study on the fine management mode of obstetric pregnancy drugs under the payment of disease diagnosis-related groups (DRG)

Abstract

Combining disease diagnosis-related grouping (DRG) with drug management index, the rational drug application management model of patients in a certain disease group was explored to promote rational drug use in obstetric care. The DRG data of obstetric patients discharged from the hospital from January 2020 to December 2022 were obtained. The target disease groups were identified based on the principle of Boston matrix analysis. The correlation between hospitalization costs and medical expenses details was studied using Spearman correlation analysis. The occurrence times and amounts of drug categories in prescriptions were counted using descriptive analysis. Drug management indicators were used to conduct cross-sectional and longitudinal cross-sectional analyses of drug use in the DRG disease group. A total of 67281 obstetric cases were included in this study, involving 32 DRG disease groups, and the overall status of the departments was overspent. The OZ13 disease group was taken as an example for follow-up analysis. The results of the correlation analysis showed that the hospitalization cost had the highest correlation with drug cost, and the use of anti-preterm drugs was the most frequent and the highest amount. Horizontal analysis of different doctors’ indicators in the OZ13 disease group found that there was a relatively large difference in drug use among different doctors, and reasonable comments were made on the abnormal medical groups. The longitudinal analysis found that the combined use of anti-preterm drugs needs further management with the aim of improving the level of clinical rational drug use.